PAN-90806

· PanOptica, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for PAN-90806, covering 2016-09-28 to 2019-07-09. Get the full timeline:

Most recent: Clinical Trial Update: Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD [Phase 1, Phase 2]